SCHEMBL21457785

SCHEMBL21457785

N#CCCN(C=O)c1ccccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 6/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
DRD3 P35462 1/20 0.38
KCNH2 Q12809 2/20 0.34
KCNA5 P22460 2/20 0.34
CHRM2 P08172 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
DRD1 P21728 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR2A P28223 1/20 0.34
SLC6A4 P31645 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28337704 0.83 CYP2D6 (0.47) CYP2D6CYP2C19ALDH1A1SMN1; SMN2DRD3
SCHEMBL22660216 0.78 HDAC1 (0.43) CYP2D6CYP2C19ALDH1A1SMN1; SMN2NPC1
SCHEMBL22048451 0.76 ALDH1A1 (0.46) CYP2D6CYP2C19ALDH1A1SMN1; SMN2KCNH2
SCHEMBL7295476 0.76 ALDH1A1 (0.50) CYP2D6CYP2C19ALDH1A1SMN1; SMN2MAPT
SCHEMBL7711638 0.75 HDAC6 (0.46) CYP2D6CYP2C19ALDH1A1SMN1; SMN2HDAC3
SCHEMBL28584939 0.75 CYP2D6 (0.41) CYP2D6CYP2C19ALDH1A1SMN1; SMN2MAPT
SCHEMBL6859239 0.73 FFAR4 (0.46) CYP2D6CYP2C19ALDH1A1SMN1; SMN2ADRA1A
SCHEMBL21837117 0.72 LMNA (0.41) CYP2D6CYP2C19ALDH1A1SMN1; SMN2MAPT
SCHEMBL6862763 0.72 HDAC1 (0.49) ALDH1A1SMN1; SMN2HDAC3HDAC4HDAC1
SCHEMBL19892686 0.71 L3MBTL1 (0.40) CYP2D6CYP2C19SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062710-A1 Method For Producing 3-(Pyridyl-2-Amino)Propionitrile And Analogues Thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2020-02-27 US disclosed
US-20200062710-A1 Method For Producing 3-(Pyridyl-2-Amino)Propionitrile And Analogues Thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2020-02-27 US disclosed
EP-3553051-A1 METHOD FOR PRODUCING 3-(PYRIDYL-2-AMINO)PROPIONITRILE AND ANALOGUES THEREOF Nippon Kayaku Kabushiki Kaisha (JP) 2019-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062710-A1 Method For Producing 3-(Pyridyl-2-Amino)Propionitrile And Analogues Thereof PDXK, PAH, PNPO CYP2D6 87/4885CYP2C19 48/4885ALDH1A1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.